Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials.

Webber M, Jackson SP, Moon JC, Captur G

Open source

DOI
10.1007/s40119-020-00199-y
Published
2020 Dec
Container
Cardiology and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40119-020-00199-y,
  title = {Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials.},
  author = {Webber M and Jackson SP and Moon JC and Captur G},
  year = {2020},
  journal = {Cardiology and therapy},
  doi = {10.1007/s40119-020-00199-y},
  url = {https://doi.org/10.1007/s40119-020-00199-y}
}

RIS

TY  - JOUR
TI  - Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials.
AU  - Webber M
AU  - Jackson SP
AU  - Moon JC
AU  - Captur G
PY  - 2020
JO  - Cardiology and therapy
DO  - 10.1007/s40119-020-00199-y
UR  - https://doi.org/10.1007/s40119-020-00199-y
ER  - 

APA

M, W., SP, J., JC, M., & G, C. (2020). Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials.. Cardiology and therapy. https://doi.org/10.1007/s40119-020-00199-y

Source records